Chugai Pharmaceutical Co., Ltd.

TSE:4519 Stock Report

Market Cap: JP¥11.2t

Chugai Pharmaceutical Past Earnings Performance

Past criteria checks 3/6

Chugai Pharmaceutical has been growing earnings at an average annual rate of 10.7%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 7.5% per year. Chugai Pharmaceutical's return on equity is 21%, and it has net margins of 32.7%.

Key information

10.68%

Earnings growth rate

10.65%

EPS growth rate

Pharmaceuticals Industry Growth3.41%
Revenue growth rate7.52%
Return on equity21.01%
Net Margin32.72%
Next Earnings Update29 Jan 2026

Recent past performance updates

Recent updates

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00

Oct 13
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00

Sep 29
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00

Sep 15
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥125.00

Chugai Pharmaceutical (TSE:4519) Will Pay A Dividend Of ¥125.00

Aug 31
Chugai Pharmaceutical (TSE:4519) Will Pay A Dividend Of ¥125.00

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Shareholders Might Be Looking For Exit

Aug 17
Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Shareholders Might Be Looking For Exit

Chugai Pharmaceutical Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Jul 26
Chugai Pharmaceutical Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

If EPS Growth Is Important To You, Chugai Pharmaceutical (TSE:4519) Presents An Opportunity

Jul 10
If EPS Growth Is Important To You, Chugai Pharmaceutical (TSE:4519) Presents An Opportunity

Chugai Pharmaceutical's (TSE:4519) Upcoming Dividend Will Be Larger Than Last Year's

Jun 10
Chugai Pharmaceutical's (TSE:4519) Upcoming Dividend Will Be Larger Than Last Year's

Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

May 21
Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year

Chugai Pharmaceutical Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 27
Chugai Pharmaceutical Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Yet to Catch Up With Its Share Price

Apr 25
Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Yet to Catch Up With Its Share Price

Calculating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Mar 17
Calculating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
User avatar

Accelerating RED Capabilities And Robust Pipeline Will Enhance Future Prospects

Emphasis on RED capabilities and innovative products aims to drive revenue growth and improve net and operating margins.

Chugai Pharmaceutical Co., Ltd. (TSE:4519) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Feb 03
Chugai Pharmaceutical Co., Ltd. (TSE:4519) Just Released Its Yearly Results And Analysts Are Updating Their Estimates

Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Share Price Could Signal Some Risk

Dec 23
Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Share Price Could Signal Some Risk

Calculating The Fair Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Dec 05
Calculating The Fair Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)

Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Oct 30
Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00

Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next

Oct 29
Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next

Revenue & Expenses Breakdown

How Chugai Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

TSE:4519 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 251,213,713397,161111,954187,420
30 Jun 251,196,214395,444111,845183,739
31 Mar 251,222,121410,150110,749181,012
31 Dec 241,170,611387,317110,098181,440
30 Sep 241,142,350386,964108,439171,068
30 Jun 241,084,570355,041108,201171,722
31 Mar 241,036,076326,373114,150173,356
31 Dec 231,111,367325,472112,580174,868
30 Sep 231,276,051336,745112,702178,244
30 Jun 231,243,437326,969107,753169,379
31 Mar 231,211,632316,15496,519158,627
31 Dec 221,259,946374,429100,760149,626
30 Sep 221,143,716370,791104,720142,201
30 Jun 221,205,696389,011106,839141,695
31 Mar 221,191,496387,359107,887141,438
31 Dec 21999,759302,995102,416137,299
30 Sep 21887,919256,46298,992132,324
30 Jun 21809,055230,57796,489126,265
31 Mar 21776,339210,61194,546121,477
31 Dec 20786,946214,73394,401117,850
30 Sep 20753,853202,59095,497116,049
30 Jun 20734,019190,59996,919110,994
31 Mar 20711,320174,062102,068108,903
31 Dec 19686,184157,560101,574107,942
30 Sep 19662,198139,54399,844105,231
30 Jun 19614,949113,07097,895102,491
31 Mar 19586,64899,63192,37999,289
31 Dec 18579,78792,48893,41699,202
30 Sep 18572,99485,85791,55398,150
30 Jun 18566,54885,28589,71096,639
31 Mar 18556,15982,10189,63198,744
31 Dec 17534,19972,71388,14792,947
30 Sep 17517,90867,70482,41190,427
30 Jun 17497,02358,14382,46589,728
31 Mar 17497,35457,59281,24885,000
31 Dec 16491,78053,59281,94185,011
30 Sep 16492,58456,56285,48183,366
30 Jun 16506,19262,53786,31384,761
31 Mar 16501,64961,04387,77284,111
31 Dec 15498,83961,12588,01883,799
30 Sep 15495,45558,89785,49285,815
30 Jun 15479,26552,22086,64883,082
31 Mar 15454,14746,78686,13481,284
31 Dec 14461,10950,98085,65580,625

Quality Earnings: 4519 has high quality earnings.

Growing Profit Margin: 4519's current net profit margins (32.7%) are lower than last year (33.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 4519's earnings have grown by 10.7% per year over the past 5 years.

Accelerating Growth: 4519's earnings growth over the past year (2.6%) is below its 5-year average (10.7% per year).

Earnings vs Industry: 4519 earnings growth over the past year (2.6%) did not outperform the Pharmaceuticals industry 10.2%.

Return on Equity

High ROE: 4519's Return on Equity (21%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/27 23:42
End of Day Share Price 2025/10/27 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Chugai Pharmaceutical Co., Ltd. is covered by 23 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Atsushi SekiBarclays
Koichi MameganoBofA Global Research
Hidemaru YamaguchiCitigroup Inc